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Splenic transitional B-cells (T1 andT2) are selected to avoid self-reactivity and to safeguard
against autoimmunity, then differentiate into mature follicular (FO-I and FO-II) and marginal
zone (MZ) subsets. Transcriptomic analysis by RNA-seq of the five B-cell subsets revealed
T1 cell signature genes included RAG suggesting a potential for receptor revision. T1 to T2
B-cell differentiation was marked by a switch from Myb to Myc, increased expression of
the PI3K adapter DAP10 and MHC class II. FO-II may be an intermediate in FO-I differen-
tiation and may also become MZ B-cells as suggested by principle component analysis.
MZ B-cells possessed the most distinct transcriptome including down-regulation of CD45
phosphatase-associated protein (CD45-AP/PTPRC-AP), as well as upregulation of IL-9R and
innate molecules TLR3, TLR7, and bactericidal Perforin-2 (MPEG1). Among the endosomal
TLRs, stimulation viaTLR3 further enhanced Perforin-2 expression exclusively in MZ B-cells.
Using gene-deleted and overexpressing transgenic mice we show that IL-9/IL-9R interac-
tion resulted in rapid activation of STAT1, 3, and 5, primarily in MZ B-cells. Importantly,
CD45-AP mutant mice had reduced transitional and increased mature MZ and FO B-cells,
suggesting that it prevents premature entry of transitional B-cells to the mature B-cell pool
or their survival and proliferation. Together, these findings suggest, developmental plas-
ticity among splenic B-cell subsets, potential for receptor revision in peripheral tolerance
whereas enhanced metabolism coincides with T2 to mature B-cell differentiation. Further,
unique core transcriptional signatures in MZ B-cells may control their innate features.
Keywords: transcriptome by RNA-seq technique, splenic transitional B-cells, follicular 1 and 2 B-cells, marginal zone
B-cells, DAP10 PI3K pathway, IL-9/IL-9R, Myb Myc,Toll-like receptors 3 and 7
INTRODUCTION
The role of B-lymphocytes is to produce antigen specific antibod-
ies to neutralize pathogens. B-cells develop in the bone marrow
(BM) where most autoreactive clones are triaged by the central
tolerance mechanisms of clonal deletion, anergy, or receptor edit-
ing (1). Surviving sIgM+ immature or transitional 1 (T1) B-cells
migrate to the spleen, where they are again tested for autoreac-
tivity. Innocuous clones are allowed to develop into transitional 2
(T2) cells (2). Observations that T1 cells are extremely sensitive to
BCR-induced apoptosis in vitro suggest that the T1-stage serves as
a peripheral tolerance checkpoint (3–7). Dysregulation of periph-
eral checkpoint can lead to autoimmune pathologies such as SLE,
RA, and MS (8–10).
The immature T2 cell stage is believed to serve as the branching
point for selection into functionally distinct mature B-cell subsets
comprised of follicular I and II (FO-I and FO-II), B1, and marginal
zone (MZ) B-cell compartments [reviewed in Ref. (11)]. FO-I cells
specialize in T cell-dependent (TD) immune responses whereas
MZ B-cells specialize in rapid T cell-independent (TI) antibody
responses and possess innate-like properties (11–13). The function
of the FO-II subset is unknown (14). A comprehensive analysis
to identify transcriptional changes associated with peripheral tol-
erance at the transitional stages and functional specialization of
mature B-cell subsets may provide a framework for hypothesis-
driven experiments to identify key processes responsible for B-cell
biological properties.
The Immunological Genome consortia (ImmGen) has pro-
vided a rich resource for gene expression data sets to the immuno-
logical community including all known mouse B-cell subsets
using microarray. Analyses of these gene expression data sets have
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produced gene-network models laying the foundation for exper-
imentally testable hypotheses for various hematopoietic lineage
cell developmental relationships and acquisition of functional spe-
cialization. However, such analysis has not been reported for the
B lineage. Here, we report bioinformatics analysis performed on
data obtained with next generation sequencing (NGS) on highly
purified B-cell subsets that are either not available from ImmGen
(FoB-II) or were phenotypically defined differently than the cur-
rent study. Our splenic B-cell populations were enriched using
a combination of schemes and to achieve maximum cell homo-
geneity defined as; T121/23DN (B220+, AA4.1+, CD23−, CD21−,
CD24hi), T2CD21int (B220+, AA4.1+, CD23+, CD21int, CD24hi),
FO-I (B220+, IgMlo, CD21int, IgD+, CD23+, CD24lo, CD9−), FO-
II (B220+, IgMhi, CD21int, IgD+, CD23+, CD24lo, CD9−), and
MZCD9+ (B220+, IgMhi, CD21hi, IgD−, CD23−, CD24int, CD9+).
We identified many novel stage-specific transcripts not iden-
tified by ImmGen data sets and associated processes. Our com-
parative analysis of transcriptomes in specific B-cell subsets has
advanced our understanding of the transcriptional networks asso-
ciated with peripheral B-cell development and selection as well as
functional specialization acquired by mature B-cell subsets. We
highlight transcripts contributing to innate MZ B-cell function
(TLR3 and Perforin-2) and demonstrate a previously unknown
function for IL-9R and CD45-AP in B-cells.
MATERIALS AND METHODS
MICE
C57BL/6 mice were purchased from The Jackson Laboratory and
maintained at University of Miami animal facility. CD45-AP−/−
(C57BL/6), IL-9R−/−, and IL-9 transgenic (Tg5) mice have been
previously described (15–17). Unless indicated otherwise, mice
used in these studies were aged between 6 and 10 weeks. These
studies were approved by the Institutional Animal Care and Use
Committee.
FLOW CYTOMETRIC ANALYSIS AND CELL SORTING
CD93+ enriched immature and CD93+CD43+ depleted mature
splenocytes were incubated with fluorochrome labeled antibodies
to sort T121/23DN, T2CD21int, FO-I, FO-II, and MZCD9+ on a BD
FACS Aria II yielding 95–99% purity as described in Figure S1
in Supplementary Material. Briefly, B-cell enrichment was per-
formed using Mouse B Lymphocyte Enrichment set-DM (BD
Biosciences). Transitional B-cells were sorted from pooled spleno-
cytes after two rounds of AA4.1 positive selection. Sorting from
DAPI−, B220+ cells produced two relatively homogeneous transi-
tional subsets. T121/23DN were AA4.1+, CD23−, CD21−, CD24hi,
whereas T2CD21int were AA4.1+, CD23+, CD21int, CD24hi. For
mature B-cell sorting, pooled splenocytes were enriched for B-
cells and simultaneously depleted of AA4.1+ (transitional) cells.
Three purified mature B-cell populations were sorted from the
DAPI−, B220+ gate. FO-I were IgMlo, CD21int, IgD+, CD23+,
CD24lo, and CD9−. FO-II were IgMhi, CD21int, IgD+, CD23+,
CD24lo, and CD9−. MZCD9+ were IgMhi, CD21hi, IgD−, CD23−,
CD24int, and CD9+.
Flow cytometric analysis of splenocytes from CD45-AP-
deficient mice and IL-9R−/−/IL-9 transgenic were performed
on a LSRII Flow cytometer and LSR Fortessa, respectively (BD
Bioscience). For intracellular staining, cells were stimulated 15 min
with IL-9 for 15 min. Cells were then fixed 10 min in 2% PFA, 90%
methanol permeabilized (30 min), washed extensively, blocked
and then incubated 1 h with anti-pSTAT, and surface marker anti-
bodies. FCM data were analyzed using FlowJo software (TreeStar).
Antibodies used are listed as follows; CD93 Biotin Clone AA4.1,
CD23 PE/Biotin Clone B3B4, CD21 FITC/PE Clone 7G6, Strep-
tavidin PE Cy7, B220 V500 Clone RA3-6B2, CD19 Clone 1D3,
CD9 Biotin Clone KCM8, pSTAT3 (pY705) Alexa Fluor 647 Clone
4/pSTAT3, pSTAT1 (pY701) Alexa Fluor 647 Clone 4a, pSTAT5
(pY694) Alexa Fluor 647 Clone 47/Stat5 (pY694) (BD Bioscience),
CD93 APC Clone AA4.1, CD24 PerCP Cy5.5 Clone M1/69, IgD
PacBlue Clone 11-26 (eBioscience), B220 Alexa 700 Clone RA3-
6B2, Streptavidin PerCP (Biolegend), IgM 649 Fab Fragment
(Jackson ImmunoResearch), CD9 FITC Clone MZ3 (Santa Cruz
Biotechnology), DAPI (Invitrogen). B220 Alexa 700, CD9 Biotin,
Streptavidin PerCP, and pSTAT antibodies were used for IL-9R/IL-
9 studies. CD21 Clone 7G6 is used for both sorting and IL-9R/IL-9
studies.
RNA ISOLATION FOR NEXT GENERATION SEQUENCING AND ANALYSIS
RNA was prepared from the sorted cells using Qiagen RLT buffer.
PolyA RNA was selected and library constructed using Illu-
mina RNA sample preparation reagents following manufacturer’s
recommendations (Illumina). RNA integrity was assessed using
a Bioanalyzer 2100 (Agilent) as well as Nanodrop 8000 Spec-
trophotometer (Thermo Scientific). Four of the five samples were
sequenced on the Illumina GAIIx using Cluster Generation Kit v4
and Sequencing Kit v4, generating 74base single-end reads. The
fifth sample (MZCD9+) was sequenced on the Illumina HiSeq2000
using the reagents provided in the Illumina TruSeq PE Cluster
Kit v3 and the TruSeq SBS Kit – HS (200 cycle) kit, generating
99base paired-end reads. Read2 was not used in this study and
read1 was trimmed to match the 74base reads generated by the
GAIIx. Quality of the RNA-seq data was reviewed using FastQC
software version 0.10.11 . Average phred-like quality scores were
>30 in all samples if calculated per-base and over 36 if calculated
per sequence. This quality was considered sufficient and no reads
were filtered out. All samples passed testing on basic parameters
in FastQC (data not shown), except sequence duplication levels
(Table S1 in Supplementary Material). Elevated duplication levels
may arise in RNA-seq due to “over-sequencing” of high abundant
transcripts as well as bias caused by non-random hexamer priming
(18). We did not remove any duplicates because there is no con-
sensus so far how it affects expression level estimations. Table S1
in Supplementary Material shows basic statistics on the samples.
Quantification of transcriptome was done in two steps as
described in TopHat protocol (19). In the first step, TopHat was
used to map the reads to the reference genome (UCSC build
mm10 GRCm38 from September 2012) with default settings and
novel splice discovery disabled. In the second step, Cufdiff was
employed to calculate FPKM values using reference transcriptome
along with BAM files from the first step for each sample. Data
were analyzed in automated fashion on the cluster hosted by the
1http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
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High-Performance Computing core in the Center for Compu-
tational Science, University of Miami. All transcript expression
below FPKM 1 was set to 1. Quantitative FPKM values were log2
transformed and converted to Z-scores. miRNA, rRNA, and hemo-
globin transcripts were removed from the analysis as these tran-
scripts likely represented artifacts (20). Table S1 in Supplementary
Material contains FPKM, log2 transformed FPKM, z-scores, and
fold-change (FC) relative to T2CD21int.
RNA species compositions (biotypes) were analyzed and visu-
alized using NOIseq package in Bioconductor2. Biotypes from
Ensemble annotation were used (Figure S1 in Supplementary
Material). Data analysis was performed using R software3. Scatter-
plot was generated using “pairs” R function. Principle component
analysis (PCA) was performed with“prcomp”R function. Z -scores
for gene expression were visualized as heatmaps using“heatmap.2”
function from “gplots” R library. Venn diagrams were generated
using “VennDiagram” library in R. Functional annotation cluster-
ing was done using DAVID bioinformatics online software (21,
22). Each term is ranked based on enrichment score along with
corresponding P value. Prioritization of clusters was based on
enrichment score using highest stringency settings. GeneGo soft-
ware (MetaCore, Thomson Reuters) was used to predict transcrip-
tion factor (TF) regulation during development. All differentially
expressed (DE) genes (FC> 2) between two subsets (or signature
genes) were used as input.
REAL-TIME PCR
RNA for quantitative Real-Time PCR (qRT-PCR) was iso-
lated using RNeasy Minikit and reverse-transcribed utilizing
Quantitect Reverse Transcription kit (Qiagen). qRT-PCR was
performed with TaqMan Fast Universal PCR Master Mix in
Step One Real-Time PCR System (Applied Biosystems). Taq-
Man primer/probes (Applied Biosystems) are as follow: Gfi1
Mm00515855_m1, Tlr3 Mm01207404_m1, Tlr7 Mm00446590_
m1, Tlr9 Mm00446193_m1, Rag1 Mm01270936_m1, Rag2
Mm01270938_m1, IL-9R Mm0043413_m1, Tnfrsf13c/BAFF-R
Mm00840578_g1,Ptprc-ap/CD45-AP Mm01236556_m1,Mpeg1/
Perforin-2 Mm01222137_g1, Hcst/Dap10 Mm01270936_m1,
Bmf Mm00506773_m1, IKKεMm00444862_m1, Tnfrsf13b/TACI
Mm00840182_m1, and Gapdh Mm99999915_g1.
WESTERN BLOT
T1, T2, and Mature B-cell (FO) subsets were sorted and western-
blotted as previously described in Ref. (7). Briefly, 20µg/lane
of total cellular extracts from FACS cells were analyzed by
immunoblotting with antibodies specific for the indicated anti-
apoptotic proteins. Anti-p38 was used as a loading control. Anti-
body information is as follows: Mcl-1 (Rockland Immunochem-
icals); Bcl-2, Bcl-xL, p38, Pim-2 (Santa Cruz Biotechnology); A1
(R&D Systems); and c-IAP2 (Cell Signaling Technology).
B-CELL ISOLATION FOR IN VITRO STIMULATION
Splenic B-cells enriched by CD43 negative selection or CD45/B220
positive selection beads (BD Bioscience) were cultured (7) and
2http://www.bioconductor.org/
3http://www.r-project.org/
stimulated with Poly(I:C) (#tlrl-pic), CL097 (#tlrl-c97), or CpG
(tlrl-1826) from Invivogen.
STATISTICAL ANALYSIS
Biological data were analyzed using Student’s t -test. All data are
represented as mean± SEM. Values of *P ≤ 0.05 were considered
statistically significant. Analysis performed using Prism software
(GraphPad).
RESULTS
TRANSCRIPTOME ANALYSIS REVEALS PREVIOUSLY UNKNOWN
RELATIONSHIPS AMONG SPLENIC B-CELL SUBSETS
We FACS-purified five splenic B-cell subsets using a combination
of schemes previously described for mouse and human B-cells (2,
4, 6, 14, 23–25). This purification scheme was used to maximize
homogeneity for RNA-Seq analysis (Figure S1 in Supplementary
Material). Hereafter, B-cell subsets will be referred to as T121/23DN,
T2CD21int, FO-I, FO-II, and MZCD9+ to denote distinction from
other sorting schemes. As shown in Figures 1A,B, the NGS data
corroborate well with cell-surface marker expression used in sort-
ing thereby confirming both phenotype and purity. qPCR further
verified the accuracy of our NGS data (Figures 2–9).
Transcriptome analysis yielded 10,851 unique transcripts
among our subsets. Approximately 19% (2057) of transcripts were
up-regulated and 16.5% (1789) were down-regulated (FC> 2) in
at least one subset relative to T2CD21int. This subset was used for
comparison because of its central position between T121/23DN and
mature subsets. MZCD9+ displayed the highest number of DE
genes, whereas FO-II had the lowest (Figure 1C). There were sig-
nificant differences in the number of DE genes detected in our
data-set compared to ImmGen (Table S1 in Supplementary Mate-
rial). For example, ImmGen identified seven genes higher in T1
versus T2 and 23 genes higher in T2 versus T1 (FC> 2 cut-off).
Our RNA-Seq data identified 375 genes higher in T121/23DN ver-
sus T2CD21int and 326 genes higher in T2CD21int versus T121/23DN
(also FC> 2 cut-off). This clearly demonstrates the utility and
advantage of our sorting scheme as well as use of RNA-Seq
technology.
Available information suggests that T1 differentiate into T2,
which give rise to mature B-cells. To determine B-cell subset rela-
tionships, we used the number of DE genes (FC> 2) to construct
a distance graph, which suggested three additional differentiation
paths (dashed lines): (1) T121/23DN to MZCD9+, (2) FO-II to FO-I,
and (3) FO-II to MZCD9+ (Figure 1D). Scatterplot and PCA analy-
sis illustrates that among our subsets, MZCD9+ was most closely
related to FO-II. Surprisingly,T121/23DN and T2CD21int were almost
equally related to MZCD9+ cells (Figures 1E,F). These three poten-
tial MZCD9+ precursors shared significant overlap in DE genes
relative to MZCD9+ (Figure 1G). This analysis also shows that FO-
II are in the middle of a follicular differentiation pathway between
T2CD21int and FO-I (Figures 1E,F). Consistently, there was a high
degree of overlap in DE genes between T2CD21int and FO-II or
FO-I (Figure 1H).
DISTINCT TRANSCRIPTION PROGRAMS DEFINE TRANSITIONAL AND
MATURE B-CELL SUBSETS
To systematically identify transcription regulators (TR) (TF
plus regulatory genes) that control co-expression of B-cell
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FIGURE 1 | Global gene expression profiles define hierarchical
relationships among splenic B-cell subsets. (A) NGS results of gene
expression profiles of each B-cell subset corroborate well with the cell-surface
marker expression shown in (B). Heatmap displaying expression of mRNAs
(median log-transformed relative fold-change) encoding cell-surface markers
that define T121/23DN, T2CD21int, FO-I, FO-II, and MZCD9+ B-cell subsets and were
used for cell sorting by FACS (see Figure S1 in Supplementary Material for
details). Immunoglubulin sequences were excluded from NGS data analysis.
Red color indicates high z -score (high expression) while blue indicates a low
z -score (low expression). (B) Histograms depict cell-surface marker
expression that define transitional (top panels) and mature (bottom panels)
splenic B-cell subsets as in (A). (C) Graphic depiction of the number of genes
differentially expressed (DE) relative to T2CD21int (FC> 2). Red circles (above
horizontal line at 0) represent the number of up-regulated genes while the
blue circles (below horizontal line at 0) represent the number of
down-regulated genes. T121/23DN, FO-I, FO-II, and MZCD9+ had 6.46, 7.17, 3.74,
and 25.39% DE genes (includes up- and down-regulated), respectively.
(D), Distance plot indicating the number of up-regulated genes (red) and
down-regulated genes (blue) in various maturation steps (FC>2). Solid arrows
indicate known paths of maturation whereas dotted arrows indicate alternate
maturation paths predicted by NGS data analysis in this study. Although we
did not sort T2-MZP (gray), it is included for completeness. It is believed to be
an intermediate between T2 to MZ B-cell differentiation. (E) Scatterplot
analysis of log-transformed NGS data showing similarity in global gene
expression between all B-cell subsets. Numbers inside intersecting boxes
indicate the percentage of similarity. Graphical representation of this
percentage is displayed on upper panels where each red dot corresponds to a
single gene. (F) Principle component analysis (PCA) using two principle
components (PC1 and PC2) where PC1 explained the majority of gene
expression differences followed by PC2. Similarity between B-cell subsets
can be ascertained by the physical difference between circles on the plot.
Both scatterplot and PCA analysis do not involve fold-change cut-offs and
involve all subset cross comparisons. (G) The number of repressed or induced
genes overlapping during differentiation from either T121/23DN, T2CD21int, or FO-II
to MZCD9+ cells. (H) The number of repressed or induced genes overlapping in
differentiation from T2CD21int to either FO-I, FO-II, or MZCD9+ cells.
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FIGURE 2 | Expression of distinct transcription regulators in splenic
B-cell subsets. Heatmap display of NGS analysis of DE transcription
regulators (including TFs) using z -scores comparing: (A) T121/23DN to T2CD21int
(FC>3 and select FC>2); (B) transitional cells (T121/23DN and T2CD21int) to all
mature B-cells (FC>3); (C) FO (FO-I and FO-II) to T2CD21int (FC>2); and
(E) MZCD9+ to all other subsets (FC>3), up-regulated (top heatmap) and
down-regulated (bottom heatmap). Pou6f1, the only gene over threefold
higher in mature relative to transitional cells, is shown in red (B). Asterisks
denote important genes discussed in the text. Many of the TFs shown are
predicted to regulate genes that are DE in the B-cell subsets (refer to Table S3
in Supplementary Material). (D) Gfi1 is down-regulated during transitional to
mature B-cell differentiation. qRT-PCR (black bars) validation of NGS results
(gray bars). qRT-PCR data are representative of three independent
experiments with FACS-sorted B-cell subsets, where each experiment utilized
pooled splenocytes from 2 to 5 mice. *P ≤0.05; **P ≤0.01. (F) Heatmap
display of transcripts encoding histone deacetylase (HDAC, top) and histone
acetylase (HAT, bottom) enzymes. (G) The number of repressed or induced
TRs that overlap during differentiation from T2CD21int to either FO-I, FO-II, or
MZCD9+ cells. (H) The number of repressed or induced genes that overlap
during differentiation from either T121/23DN, T2CD21int, or FO-II to MZCD9+ cells.
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FIGURE 3 |T121/23DN and MZCD9+ B-cell subsets are highly enriched for
signature genes. (A–D) RAG1 and RAG2 transcripts are prominent
T121/23DN signature genes. Heatmap displaying z -scores of T121/23DN
signature genes (FC>4) that are uniquely up-regulated (A) or
down-regulated (B). qRT-PCR analysis validated NGS results showing
RAG1 and RAG2 are up-regulated T121/23DN signature genes. (C) RAG1
mRNA expression by qRT-PCR (black bars) and RNA-Seq (gray bars) and
(D) RAG2 mRNA expression analyzed as in (C). qRT-PCR data represent
three independent experiments with FACS-sorted B-cell subsets, where
each experiment utilized pooled splenocytes from 2 to 5 mice *p≤0.05.
(E,F) MZCD9+ B-cells show highest number of signature genes. Heatmap
displaying z -scores of MZCD9+ (FC>4) that are uniquely up-regulated (E) or
down-regulated (F). Asterisks in heatmaps denote genes discussed in the
text. Due to the high number of up-regulated signature genes in MZCD9+
cells, genes below Ahr (57 out of 146) were removed but can be
referenced in Table S1 in Supplementary Material.
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FIGURE 4 | Differentially expressed genes define apoptotic and
proliferative potential of transitional and mature B-cell subsets.
Heatmap display of NGS data analysis of genes encoding (A) anti-
apoptotic, (B) pro-apoptotic, (E) cyclin dependent kinases (CDKs),
(F) cyclins, (G) E2F cell cycle transcription factors, and (H) proliferation
inhibitors, using z -scored NGS gene expression data. Asterisks denote
important genes discussed in the text. (C) qRT-PCR analysis (black
bars) validated NGS results (gray bars) showing upregulation of Bmf in
T121/23DN cells. qRT-PCR data are representative of three independent
experiments with FACS-sorted B-cell subsets, where each experiment
utilized pooled splenocytes from 2 to 5 mice. *P ≤0.05; **P ≤0.01;
***P ≤0.001. (D) Western blot of anti-apoptotic proteins showing key
survival factors such as Bcl-2 increase during differentiation. p38
served as a loading control.
stage-specific genes, we exploited 1581 TRs recently used to define
transcriptional architecture of human hemato- and lympho-
poiesis (26). A major shift in the expression of TRs accompanied
T121/23DN to T2CD21int differentiation (Figure 2A). These included
Myb, Sp3, and Sox4 at the T121/23DN stage whereas Myc, Bmyc,
Rarα, Nr4a1/Nur77, and Cebpb were prominent at the T2CD21int
stage. These TRs are predicted to regulate key biological processes
with Myc alone regulating over 19% of DE genes at the T2CD21int
stage (Tables S2 and S3 in Supplementary Material).
We also identified TFs relevant for transitional B-cell mat-
uration, e.g., down-regulation of B-cell differentiation TF Gfi1
coincided with differentiation of transitional into mature B-cells
www.frontiersin.org February 2015 | Volume 6 | Article 30 | 7
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FIGURE 5 | Gene expression profiles predict PI3K/Ras signaling
stabilizes Myc during B-cell development. Heatmap display of
(A) Myc associated genes including Myc binding partners Pam and Max,
(B) sphingosine receptors possibly mediating Pam/mTOR signaling,
(C) inositol kinase signaling molecules including Dap10 (bottom) as
well as inositol phosphatases (bottom), (E) Ras family genes, and
(F) Serine/threonine phosphatases. (D) qRT-PCR analysis (black bars)
validated NGS results (gray bars) showing upregulation of Dap10 starting
at the T2CD21int stage. qRT-PCR data are representative of three
independent experiments with FACS-sorted B-cell subsets, where each
experiment utilized pooled splenocytes from 2 to 5 mice. *P ≤0.05;
**P ≤0.01.
(Figure 2D) (27). Conversely, proliferation-promoting Pou6f1
was enriched over three-fold in mature B-cells (Figure 2B) (28).
T2CD21int to FO differentiation is regulated mainly by metal-
ion binding TFs (Table S3 in Supplementary Material). Further,
more TRs were up-regulated in FO-I relative to FO-II consistent
with FO-II being less differentiated (Figure 2G). GeneGo analysis
predicted Tbet, Rar, and Titf/Nkx2-1 TFs were required for differ-
entiation into FO-I whereas Nfatc2 is likely to be essential for FO
B-cell function (Table S2 in Supplementary Material). Zfp467 and
Stat4 were specifically enriched in FO-I and FO-II (Figure 2C) and
may therefore selectively regulate FO differentiation and function.
Interestingly, Klf2 was predicted to drive FO-II→ FO-I terminal
differentiation suggesting expression of Klf2 may determine FO-II
fate into either FO-I or MZ (Table S3 in Supplementary Mate-
rial). These data reinforce a T2/FO B-cell differentiation cluster
requiring relatively few DE TRs.
T2CD21int to MZCD9+ differentiation required substantial and
unique TR rewiring, particularly TFs with zinc-finger and PAS
domains (Figure 2E; Table S3 in Supplementary Material). Many
DE TRs involved in T121/23DN, T2CD21int, or FO-II differentiation
into MZCD9+ overlapped suggesting commonality in MZCD9+
fate (Figure 2H). Signature MZCD9+ TRs included those not
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Kleiman et al. Mouse peripheral B-cell transcriptome
FIGURE 6 | (A,B) Expression of genes associated with immune competence
from the T2CD21int stage and (C–F) upregulation of genes associated with
activated and innate characteristics of MZCD9+ cells. Heatmap display of
(A) MHC class II (top) and MHC class I (bottom), (B) TNF ligands (top) and TNF
receptors (bottom), and (C) NFκB signaling components (top) and NFκB
inhibitors (bottom). qRT-PCR analysis (black bars) validated NGS results (gray
bars) of (D) BAFF-R, (E) TACI, and (F) IKKε. qRT-PCR data are representative of
three independent experiments with FACS-sorted B-cell subsets, where each
experiment utilized pooled splenocytes from 2 to 5 mice. *P ≤0.05;
**P ≤0.01.
previously linked to MZCD9+ differentiation and function. One
example is Myc binding protein 2 (PAM), which is expressed
4.5-fold higher in MZCD9+ compared to other subsets. We also
observed that many TFs [Jund, Junb, Jun, Fos, and Klf2 (29)] were
uniquely down-regulated in MZCD9+ (Figure 2D). TFs uniquely
up-regulated in MZCD9+ cells were predicted to regulate many
genes, including those involved in innate immune response (Table
S2 in Supplementary Material). Reduced HDAC and distinct HAT
expression profile in MZCD9+ cells was consistent with dramati-
cally altered transcriptome (Figure 2F). Additionally, we observed
Nfat TFs (Nfat5, Nfatc1) as well as Nfat activator Nfam1 were
particularly enriched in MZCD9+ cells (Table S1 in Supplemen-
tary Material). Thus, we have identified previously known and
unknown TRs that contribute to MZCD9+ differentiation and
function.
TRANSCRIPTOME ASSOCIATED WITH PERIPHERAL B-CELL TOLERANCE
To systematically define transcriptional programs that regulate
alterations in fundamental processes/genes and eventual biolog-
ical properties of individual B-cell subsets, we identified genes
uniquely expressed or repressed termed signature genes (Figure 3;
Table S1 in Supplementary Material). T121/23DN were enriched
in mitosis factors including cyclins, microtubule motor activ-
ity, nucleoside binding, DNA biosynthesis and recombination,
and serine/threonine kinases and were deficient in MHCII, B-cell
mediated immunity, positive regulation of NFκB, and cytokine
and metabolic activity (Figures 3A,B; Table S3 in Supplementary
Material). Given that DNA recombination is critical for recep-
tor editing, we confirmed that T121/23DN cells uniquely expressed
RAG1 and RAG2 (Figures 3C,D). Although previous reports have
shown differential RAG expression in splenic transitional B-cells,
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FIGURE 7 | CD45-AP limits premature entry of transitional B-cells into the
mature B-cell pool. (A) Heatmap display of protein tyrosine phosphatases
including tyrosine phosphatase PTPN22, CD45/Ptprc, and CD45 binding
partner CD45-AP/Ptprc-ap (astericks). (B) qRT-PCR analysis validated NGS
results showing CD45-AP is down-regulated in MZCD9+ B-cells. CD45-AP
mRNA expression by qRT-PCR (black bars) and RNA-Seq (gray bars). qRT-PCR
data are representative of three independent experiments with FACS-sorted
B-cell subsets, where each experiment utilized pooled splenocytes from 2 to
5 mice. (C) Phenotypic analysis of splenic B-cells isolated from WT and
CD45-AP−/− mice. Histogram showing percent of CD19+ B-cells within
splenocytes (top panels). CD19+ gated B-cells were further analyzed for
transitional (T1 and T2), FO, and MZ B-cells. CD23 versus CD21 staining is
used to differentiate MZ (CD21hi, CD23lo) and FO (CD21lo-int, CD23+). IgM
versus CD21 allows for analysis of additional subsets such as T1 (IgMhi,
CD21−), T2 (IgMhi, CD21lo-int), and preMZ (MZP). Data are representative of
three mice. Bar graph representation of B-cell subset percentages (D) and
numbers from three mice (E). (F) Absence of CD45-AP modestly affects
cell-surface display of B220 protein. FCM analysis of WT versus CD45-AP−/−
splenic B-cell subsets for the expression of B220. (G) MZCD9+ have the
highest surface expression of B220. Post-sort surface B220 expression of
sorted FO-I, FO-II, and MZCD9+ B-cells (refer to Figure S1 in Supplementary
Material) and plotted in (H) bar graph. *P ≤0.05; **P ≤0.01; ***P ≤0.001.
we observed much greater FC possibly because our sorting scheme
excluded CD21+ and CD23+ cells (30).
Apoptosis and cell cycle control are integral to transitional B-
cell tolerance and maturation. Unexpectedly, we did not observe
a generalized enrichment of apoptosis and/or cell cycle regu-
latory genes in any B-cell subset. However, T121/23DN subset
was enriched in select pro-apoptotic genes (Bmf and Apaf1)
suggesting their role in negative selection (Figures 4A–C). As
expected, apoptosis-resistant T2CD21int cells were enriched for
anti-apoptotic genes Bcl-2a1b/d and Bcl-2. Bcl-2 and other anti-
apoptotic protein levels largely corresponded with the gene expres-
sion (Figure 4D). T121/23DN cells also expressed higher cell cycle
repressors Rb1 and Cdkn1b whereas T2CD21int cells expressed
slightly higher Myc-target gene cyclin Ccnd2, a key regulator
of proliferation (31) (Figures 4E–H). These findings are con-
sistent with T121/23DN sensitivity to apoptosis and tolerance
checkpoint.
TRANSCRIPTOME ASSOCIATED WITH B-CELL MATURATION AND
IMMUNE COMPETENCE
Myc is kept in check in T121/23DN and up-regulated in T2CD21int
and beyond (Figure 5A). Due to their significance in stabi-
lizing Myc, we focused on PI3K and Ras signaling (32, 33).
We found T121/23DN cells were significantly deficient for PI3K
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FIGURE 8 | Increased IL-9R expression manifests in enhanced
responsiveness of MZCD9+ B-cells to IL-9. Increased IL-9R expression
manifests in enhanced responsiveness of MZCD9+ B-cells to IL-9. (A) Heatmap
display of cytokine and cytokine receptors including IL-9R and its
heterodimerization partner IL-2Rg (astericks). (B) qRT-PCR analysis validated
NGS results showing IL-9R is a MZCD9+ up-regulated signature gene. IL-9R
mRNA expression by qRT-PCR (black bars) and RNA-Seq (gray bars). qRT-PCR
data are representative of three independent experiments with FACS-sorted
B-cell subsets, where each experiment utilized pooled splenocytes from 2 to
5 mice. (C–D) IL-9R is dispensable for splenic B-cell development. Bar graph
displaying MZ (B220+, CD21hi, CD23lo, IgMhi) and FO (B220+, CD21lo-int,
CD23hi, IgM+) B-cell subset percentages (C) and numbers (D) from Balb/c
control versus IL-9R−/− mice. FO represents follicular B-cell populations (FO-I,
FO-II, and T2 B-cells). B1a B-cells were gated as (B220+, CD23−, IgMhi, CD5+).
Data are representative of six mice. Transgenic over-expression of IL-9 does
not affect B-cell development. (E) Bar graph displaying MZ (B220+, CD21hi,
CD23lo, IgMhi) and FO (B220+, CD21lo-int, CD23hi, IgM+) B-cell percentages
from FVB WT control and IL-9 transgenic (Tg5) mice. Data are representative
of three mice. (F,G) Bar graph displaying MZ (B220+, CD21hi, CD23lo, IgMhi)
and FO (B220+, CD21lo-int, CD23hi, IgM+) B-cell subset percentages (F) and
numbers (G) from Balb/c IL-9R+/− control mice and IL-9 transgenic (Tg5)
heterozygotes (IL-9R+/−, IL-9 Tg+/−) mice. Data are representative of six mice.
(H,I) MZ B-cells display reduced cell-surface CD9 in transgenic mice
overexpressing IL-9. Left bar graphs show CD9 mean fluorescence intensity
(MFI) of MZ B-cells (B220+, CD21hi, CD23lo)
(Continued )
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FIGURE 8 | Continued
comparing WT versus IL-9 Tg mice. Right bar graphs show the percentage
of cells displaying CD9+ positivity comparing MZ versus FO B-cells
(B220+, CD21lo-int, CD23+). Bar graphs in H and I are representative of
three mice. (J,K) Short term IL-9 induces STAT3 activation selectively in
MZ B-cells. (J) FCM analysis of pSTAT3 in FVB splenic MZ (B220+, CD21hi,
CD23lo) versus FO (B220+, CD21lo-int, CD23+) B-cells stimulated or
non-stimulated (NS) with bacculo-produced IL-9 (3.5 ng/mL) for 15 min at
37°C. FO represents follicular B-cell populations (FO-I, FO-II, and T2
B-cells). Numbers in quadrants represent the percentage of cells. (K) Bar
graph comparing the percentage of pSTAT3 positive cells in MZ versus FO
B-cells. (L) Bar graph comparing the percentage of pSTAT3 positive cells in
CD9+ versus CD9− MZ B-cells. Data from (H–J) are representative of five
mice. (M–O) IL-9 induction of pSTAT3 is independent of genetic
background. Balb/c wild-type mice were treated as in J and stained for
either pSTAT3, pSTAT1, or pSTAT5. pSTAT3 data (M) represent three mice
whereas pSTAT1 (N) and pSTAT5 (O) data represent two mice. *P ≤0.05;
**P ≤0.01; ***P ≤0.001; ****P ≤0.0001.
FIGURE 9 | MZCD9+ B-cell subset is poised for innate immune
responses. Heatmap display of NGS data showing enrichment of (A) TLR
and (D) innate immune sensors/effector genes. Asterisks denote
important genes discussed in the text. qRT-PCR analysis validated NGS
results showing MZCD9+ express highest amounts of TLR3, TLR7 and
Perforin-2. qRT-PCR (black bars) and RNA-Seq (gray bars) of (B) TLR3,
(C) TLR7, and (E) Perforin-2. qRT-PCR data are representative of three
independent experiments with FACS-sorted B-cell subsets, where each
experiment utilized pooled splenocytes from 2 to 5 mice. (F) qRT-PCR of
Perforin-2 mRNA fold-change after stimulation with endosomal TLR
agonists. B220 positively selected cells (>95% purity) were stimulated
18 h with either TLR3 agonist Poly(I:C), TLR7/8 agonist CL097, or TLR9
agonist CpG at 1µg/mL and compared to NS. (G) qRT-PCR of Perforin-2
mRNA fold-change using B220 positive (>95% purity) or CD43 negative
(~90% purity) B-cells stimulated with Poly(I:C) as in (F). Data are
representative of four independent experiments. (H) qRT-PCR of Perforin-2
mRNA fold-change using FACS derived MZCD9+ or FO-I B-cells treated with
Poly(I:C) as in (F). *P ≤0.05; **P ≤0.01.
adaptor protein HCST (DAP10) as well as Ras signaling mol-
ecules RasGef1b and RafGef4 (Epac2) (Figures 5C–E). Instead,
T121/23DN cells expressed twofold more PI3K antagonist PTEN
(34) and highest catalytic and regulatory subunits of Protein
phosphatase 2A (PP2A/Ppp2ca, B56alpha/Ppp2r5a) to increase
Myc degradation (Figures 5C,F) (35). Stunted Myc expression
in T121/23DN cells likely prevents autoreactive B-cell survival and
maturation. Differentiation past T121/23DN stage coincided with
a significant upregulation of MHCII genes (H2-Ab1/Aa/Eb1/Oa),
a hallmark of immune competence (Figure 6A; Table S3 in Sup-
plementary Material). Consistently, T2CD21int were also enriched
for Fcer1g, CR2/CD21, complement factors, Icosl and TNFα
(Figure 6B; Table S3 in Supplementary Material).
In contrast to T121/23DN, Ppp2ca and Ppp2r5a were lowest in
MZCD9+, inversely correlating with the Myc levels (Figure 5F).
Enhanced Myc along with a distinct transcriptome, including
many signature genes, contribute to the activated state of MZCD9+
cells (Table S1 and S3 in Supplementary Material). Consistent
with this state, MZCD9+ were enriched for genes that positively
regulate NFκB signaling (Rel, Traf1, Ikβkε, Ikkα, Malt1, PKCβ).
Additionally, negative NFκB regulator (IκBβ) as well as prolif-
eration inhibitor Cdkn2d were exclusively down-regulated (31,
36) (Figures 6C,F). However, to prevent overactivity of Myc,
MZCD9+ B-cells also have heightened expression of negative reg-
ulators Inpp5f, Inpp4a, PTEN, Rap1gap, down-regulated Mapk3,
and increased expression of NFκB negative regulators Zfand6, Itch,
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Rnf11, and most notably Cbl (Figures 5C,E and 6C) (31, 37–39).
Overall, these data suggest MZCD9+ cells are primed for quick
immune responses including TACI-dependent T-independent
immune response (Figure 6E) (40). Finally, MZCD9+ cells were
also enriched for MHCI molecules, especially H2-Q6 suggesting
MZCD9+ cells are more suited to present certain types of antigens
consistent with their known ability to present glycolipid antigens
via CD1d (Figure 6A) (13). Interestingly, transcriptome analysis
comparing follicular subsets showed FO-I were enriched in histone
gene expression while FO-II were enriched for genes involved in
lymphocyte and complement activation as well as RNA binding
(Figure S1J in Supplementary Material; Table S3 in Supplementary
Material). This indicates FO-II share some innate-like qualities
with MZCD9+ cells, albeit not as robustly (e.g., CD36 and Perforin-
2, Figure 9B), and that they are likely capable of context-dependent
plasticity (11).
CD45-AP REGULATES MZ B-CELL HOMEOSTASIS
Bioinformatic analysis indicated enhanced regulation of kinase
activity in MZCD9+ cells (Table S3 in Supplementary Material).
For example, PTPN22 tyrosine phosphatase, a negative regula-
tor of BCR signaling, is expressed highest in MZCD9+ relative to
the B-cell subsets analyzed (Figure 7A). Of note, polymorphisms
in PTPN22 that render B-cells (and T and innate cells) hyper-
responsive and are associated with many autoimmune diseases
(41, 42). Conversely, CD45 phosphatase is a major positive regula-
tor of BCR-induced kinase activity (15). Kinase activity is critical
for BCR signaling strength, which has been proposed to regu-
late MZ versus FO-cell fate (11). Our NGS and qRT-PCR data
revealed that CD45-associated protein (CD45-AP/Ptprc-ap) was
2.5-fold reduced in MZCD9+ relative to FO-I cells (Figures 7A,B).
CD45-AP is one of the most abundantly expressed genes (FO-
I FPKM= 1500). Up to 75% of CD45-AP protein complexes
with and potentially positively regulates phosphatase activity of
CD45, a key positive regulator of BCR signaling (15). However,
the role of CD45-AP in B-cell development and homeostasis
remains unknown. Therefore, we analyzed splenic B-cell devel-
opment in mice deficient for CD45-AP (CD45-AP−/−) (15). FCM
analysis of CD45-AP−/−mice revealed reduced percentage of tran-
sitional B-cells (T1 and T2) despite an overall increase in B-cell
numbers (Figures 7C–E). Although absolute numbers of FO B-
cells were increased, their proportion did not. In contrast, both
proportions and absolute numbers of MZ B-cells were signifi-
cantly increased (Figures 7C–E). Additionally, absence of CD45-
AP slightly reduced cell-surface B220 (CD45) potentially further
reducing BCR signaling strength (Figure 7F). These results sug-
gest that altered signaling by loss of CD45-AP either facilitates
transitional B-cell maturation or survival and/or proliferation of
mature B-cell subsets.
SELECTIVE EXPRESSION AND FUNCTION OF IL-9R IN MZ B-CELLS
IL-9R is uniquely enriched in MZCD9+ cells (Figures 8A,B), even
when compared to other immune cell populations (43). IL-9R
interaction with IL-9 regulates inflammation, humoral immunity,
and B1 B-cell expansion (17, 44–48). However, IL-9R function in
MZ B-cells remains unknown. Therefore, we tested a role for IL-
9R in MZ B-cell development and homeostasis using mice with
IL-9R gene deletion and transgenic mice over expressing IL-9.
Distribution and numbers of splenic B-cell subsets in IL-9R defi-
cient mice were comparable to controls, precluding a role for IL-9R
in splenic B-cell development or homeostasis (Figures 8C,D).
Likewise, IL-9 transgenic (Tg) mice did not show any signif-
icant alterations in splenic B-cell populations in two different
genetic backgrounds, FVB and Balb/c (Figures 8E–G) (17, 48).
However, a curious finding was that in IL-9 Tg mice MZ B-cells
down-regulated cell-surface expression of CD9 in both genetic
backgrounds compared to wild-type control mice (Figures 8H,I).
These data are consistent with the highest level of IL-9R expres-
sion in MZ B-cells, as predicted by our RNA-Seq and RT-PCR data.
Taken together, these results demonstrate that IL-9 and IL-9R are
dispensable for B-cell development and homeostasis.
Down-regulation of cell-surface CD9 in MZ B-cells by over-
expression of IL-9 suggested that IL-9/IL-9R signaling might be
consequential in MZ B-cells. Therefore, we sought to experimen-
tally test whether IL-9R in MZCD9+ B-cells transmits intracellular
signals. We measured Stat3 phosphorylation by FCM following
IL-9 treatment. Compared to non-stimulated cells, low-dose IL-9
induced robust Stat3 phosphorylation primarily in MZ B-cells
(Figures 8J,K). A much smaller increase was also observed in
FO B-cells. Activation of pSTAT3 within MZ B-cells was higher
in the CD9+ than CD9− fraction (Figure 8L). From preferential
MZCD9+ B-cell response to IL-9, it seems that this cell population
may express highest cell-surface IL-9R protein, consistent with
highest IL-9R transcript levels (NGS). Additional experiments
showed that in addition to Stat3, IL-9 induced phosphorylation
of Stat1 and Stat5 in MZ B-cells. Since, these experiments were
carried out with B-cells isolated from Balb/c mice, the results
also demonstrate that selective responsiveness of MZ B-cells to
IL-9 is independent of the genetic background (Figures 8M–O).
To our knowledge this is the first report to demonstrate IL-9/IL-
9R signaling in MZ B-cells. However, additional experiments are
needed to determine the effects of this signaling on MZ B-cell
function.
MZCD9+ CELLS SELECTIVELY EXPRESS GENES ASSOCIATED WITH
INNATE IMMUNITY
Although MZ B-cells have been proposed to have innate-like
properties, a comprehensive transcriptome analysis of these char-
acteristics has not been performed (13, 49). Our analysis of innate
immune sensors revealed that MZCD9+ cells are enriched in the
RNA sensing molecules Tlr3, Tlr7, and Nlrc3/Nod3, the bacterial
peptidoglycan sensors Nod1/2/3 and Nlrc4 and the DNA sensors
Tlr9 and Prkdc (Figures 9A–E) (50). Innate effector molecules
such as respiratory burst oxidase gene Cybb, autophagy associ-
ated gene Pik3r4/p150, and the recently identified intracellular
bactericidal Perforin-2 are also highly enriched in MZCD9+ cells
(Figure 5C and Figures 9B,F) (51, 52). MZCD9+ cells are also
enriched for IKKε, which provides a critical link to innate immune
pathways under NFκB control. To our knowledge, this is the first
report to suggest a biased use of this innate pathway in MZCD9+
B-cells (Figures 6C,F) (53).
We chose TLR3 for functional assessment because it is exclu-
sively expressed in MZCD9+ cells. We show that in total B-
cells TLR3 agonist Poly(I:C) was unique among endosomal TLR
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agonists by inducing a threefold increase in Perforin-2/MPEG1
transcript (Figure 9G). Using sorted cells we showed that MZCD9+,
but not FO-I cells, exclusively induced Perforin-2 (Figure 9H).
These results show that MZCD9+ cells uniquely and functionally
express TLR3, which can endow bactericidal function to MZCD9+
B-cells through Perforin-2 induction.
DISCUSSION
This study is the first to report the mRNA transcriptome obtained
by RNA-Seq of mouse splenic B-cell subsets (43, 54–58). Our data
support the hypothesis that MZCD9+ subset may arise from multi-
ple precursors. Differentiation from T121/23DN would theoretically
bypass CD23 expression (59). Further support for T121/23DN to
MZCD9+ pathway comes from shared deficiency of N-regions and
an increase in TLR9 and Aiolos expression, both of which promote
MZ differentiation (60–62). While FO-II could differentiate into
MZ, they are most closely related to FO-I. PCA analysis addition-
ally supported FO-II to be an intermediate of FO-I subset, possibly
mediated by Klf2.
Enhanced expression of pro-apoptotic gene (Bmf) in T121/23DN
relative to T2CD21int supports the notion that autoreactive B-
cell are deleted by mitochondrial pathway of apoptosis at the
T1-checkpoint (63). Our novel finding that Serine incorporator
(Serinc5) is exclusively expressed in T121/23DN cells may provide an
additional mechanism of cell death by altering membrane compo-
sition and BCR signaling (64) (Figure 3A). Furthermore, we found
expression of genes associated with DNA recombination (RAG1,
RAG2, Ligase 4) exclusively in T121/23DN cells suggesting recep-
tor revision. These data suggest apoptosis and receptor revision
contribute to peripheral tolerance at the T1-checkpoint.
We also found that up-regulated T121/23DN signature gene
Akap12 may uphold the T121/23DN stage by interfering with activa-
tion, migration, and proliferation (Figure 3A) (65). Consistently, it
is dramatically down-regulated in proliferative T2CD21int cells. To
our knowledge, this is the first report to identify down-regulation
of Akap12 as an indicator of proliferation in splenic B-cells.
Myb to Myc switch from T121/23DN to T2CD21int was highly
consequential as these TFs regulated a substantial proportion of
DE genes. We predict Rarα expression contributes to Myb down-
regulation (66). Onset of Myc expression in T2CD21int cells pro-
foundly influenced gene expression comprising one-fifth of all DE
genes (67) conferring metabolic fitness and likely driving survival,
proliferation and differentiation of T2CD21int into mature B-cells
(4, 31, 68, 69). Consistently, our data show that MZCD9+ expressed
highest levels of Myc as well as Myc binding/regulatory proteins
PAM and Max (Figure 5A). Consistent with their resting state, FO-
I cells express the least Myc of mature subsets, but express highest
Bmyc, which we suggest transcriptionally represses Myc (70). Both
heightened expression of Bmyc in FO-I and its potential function
in B-cells have not been previously reported.
Our data also suggest uncoupling of the BCR from growth,
metabolic, and Myc pathways (PI3K and Ras/ERK) contribute to
the distinct T121/23DN cell biology. This may be explained by our
novel finding that the PI3K pathway may be may not be fully acti-
vated in T121/23DN cells due to severely reduced levels of the Dap10
adapter for PI3K (71). This genetic data are supported by exper-
imental evidence showing T1 cells only weakly activate the PI3K
pathway (via Akt phosphorylation) (3, 5). Additionally, increased
expression of negative regulators of BCR signaling PTEN, CD72,
and PP2A would further limit the PI3K/Myc pathway in T121/23DN
cells (34, 35, 72). Differentiation into T2CD21int is also accom-
panied by Bcl-2 transcript and protein. Heightened expression
of both Myc and Bcl-2 is a highly potent combination (highest
in MZCD9+) promoting survival during Myc-driven proliferation
and frequently occurs in various B-cell lymphomas (73, 74). We
suggest that survival at the T2CD21int stage is also supported by
TNFα as T2CD21int and mature B-cells express only pro-survival
TNFR2 (75). Together, these data point to a previously unknown
PI3K- and Myc-driven transcription program, facilitated by TNFα,
which distinctly controls metabolic activity in the two transi-
tional B-cell subsets to allow negative selection in T121/23DN and
proliferation and differentiation in T2CD21int B-cells.
With the gain of survival and proliferation potential, T2CD21int
cells begin to express MHCII and its transcriptional activator,
CIITA as well as the immune modulator Icosl. While the altered
gene expression endows T2CD21int cells immune competence, it
also prevents inadvertent B-cell mediated T cell activation, which
can lead to autoimmune diseases (76). As T2CD21int cells are poised
for further differentiation in the splenic follicles, they express
LTα and LTβ and facilitate follicular architecture and secondary
lymphoid organogenesis (Table S1 in Supplementary Material)
(77, 78).
Our analysis of CD45-AP−/− mice revealed an increase in the
percentage and numbers of total B-cells due to an increase in
mature B-cells, particularly MZ type, similar to CD45−/− mice
(79, 80). However, in contrast to CD45, CD45-AP appears to
restrict transitional B-cell differentiation, especially to MZ B-
cell fate or it is required for maintaining homeostasis within the
mature B-cell compartment. Additionally, reduced B220/CD45
surface expression in CD45-AP−/− B-cells suggested that CD45
and CD45-AP are reciprocally dependent for protein stability (81–
85). A reduction in CD45 and consequent phosphatase activity
would reduce BCR signal strength. Despite conflicting reports con-
cerning CD45-AP’s role in receptor signaling (15, 81, 83, 86–89),
we propose CD45-AP effects BCR signaling either in transitional
cells to prevent their premature entry to the mature B-cell pool or
their survival and proliferation. Thus, CD45-AP regulates splenic
B-cell homeostasis (79).
Our transcriptome data showing significantly higher IL-9R
together with high levels of heterodimer partner IL-2Rγ sug-
gested a potential function for IL-9R in MZCD9+ B-cells. While
IL-9R did not play a role in MZ B-cell development, it may play
a role in MZ B-cell function as exposure to IL-9 induced phos-
phorylation of Stat proteins. Activation of Stat proteins, particu-
larly Stat3, is important in host defense (90). Consistently, over-
expression of IL-9 has previously been shown to result in increased
immunoglobulins before and after immunization (17, 44–46).
These findings suggest a potential role for IL-9R-dependent acti-
vation of MZ B-cells in immune response (91). Although MZCD9+
B-cells specialize in TI antibody responses, elevated IL-9R suggests
that the TD antibody responses may also be differently regulated in
this B-cell subset. Consistently, key regulators of antibody response
in FO B-cells (IL-4R and IL-21R) are specifically down-regulated
in MZ B-cells (Table S1 in Supplementary Material).
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A striking finding was that long-term activation of MZ B-
cells by IL-9 in transgenic mice dramatically down-regulated CD9
surface levels possibly relating to its function in BCR signaling,
migration, adhesion and homing (92–94). However, CD9 defi-
ciency does not alter B-cell development or humoral immunity
perhaps due to functional redundancy (95). Taken together, IL-
9/IL-9R induction of Stat pathway and down-regulation of CD9
suggests that IL-9R contributes to MZ B-cell function.
Accumulating evidence indicates MZ B-cells function in both
innate and adaptive immunity (13) and we identified many DE
transcripts with unknown functions in this subset. One such mol-
ecule was PAM, which has not been previously linked with MZ
B-cell function. This E3 ubiquitin ligase mediates mTOR activa-
tion through sphingosine-1-phosphate receptors, of which S1p1
and S1p3 are both highly enriched in MZCD9+ cells (Figure 5B)
(96, 97). Given that mTOR promotes B-cell activation, matura-
tion, antibody production, and survival, we speculate PAM bridges
mTOR activation with sphingosine receptor signaling impart-
ing MZCD9+ with unique functionality (98). We provided evi-
dence that MZCD9+ cells possess unique innate sensing ability
through expression of various PAMP receptors such as bacterici-
dal Perforin-2. Further,we showed that TLR3 induction exclusively
induced Perforin-2 in MZCD9+ cells (51, 52). Thus, through a
unique transcription program, MZCD9+ cells become hardwired
to recognize infectious agents and respond quickly to bridge the
adaptive immune response.
In summary, our data have identified several genes and gene
clusters, which have not previously been linked to specific splenic
B-cell subsets. These data revealed potential novel developmen-
tal relationships among splenic B-cell populations, and indicated
receptor revision in T121/23DN may contribute to peripheral tol-
erance. The first major shift in the transcription program accom-
panied T121/23DN→T2CD21int differentiation, which was domi-
nated by Myc and PI3K/Ras pathways indicating enhanced meta-
bolic activity, survival (via Bcl-2) and proliferation and these
alterations were largely shared with mature B-cell subsets. Our
analysis also demonstrated that CD45-AP is important for periph-
eral B-cell homeostasis while IL-9R participates in MZCD9+ cell
function. Highly selective expression and function of IL-9R sug-
gests that in MZCD9+ B-cells, TD antibody responses are regu-
lated via mechanisms distinct from FO B-cells. Further, MZCD9+
cells expressed genes that are known to confer innate effector
functions as exemplified by expression of PAMPs, TLR3, and
Perforin-2. Thus, MZCD9+ B-cells are uniquely suited for TI anti-
body response, may distinctly regulate TD antibody response
and possess broader innate immune capabilities than previously
appreciated.
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